Amiodarone hydrochloride tablets for life-threatening ventricular arrhythmias

Amiodarone hydrochloride tablets are prescribed oral medications used to treat serious and life-threatening heart rhythm disorders, specifically recurrent ventricular fibrillation and unstable ventricular tachycardia in adults. Due to significant risks of toxic effects affecting lungs, liver, and heart, amiodarone hydrochloride is reserved for patients who have not responded to or cannot tolerate other antiarrhythmic drugs.

Amiodarone hydrochloride tablets are indicated for adult patients with:

• Documented, life-threatening recurrent ventricular fibrillation.
• Life-threatening recurrent hemodynamically unstable ventricular tachycardia.

The medication is used when other antiarrhythmic drugs have failed or are not tolerated.

Amiodarone Hydrochloride

Amiodarone works by affecting the electrical signals in the heart to restore normal rhythm and prevent dangerous irregular heartbeats. It acts as an antiarrhythmic agent that modulates heart rhythm stability.

Dosage is individualized based on arrhythmia severity and patient response, using the lowest effective dose. The usual dosing schedule is:

1. Loading dose: 800 to 1600 mg daily orally until initial therapeutic response, typically 1 to 3 weeks.
2. After control is achieved or side effects appear, reduce to 600 to 800 mg daily for 1 month.
3. Maintenance dose: typically 400 mg daily thereafter.

Amiodarone should be taken consistently with regard to meals. For total daily doses ≥ 1000 mg or if gastrointestinal side effects occur, divided doses with meals are recommended.

Before starting treatment, baseline tests including chest X-ray, pulmonary function, thyroid function, and liver enzymes are required. Electrolyte imbalances (hypokalemia, hypomagnesemia, hypocalcemia) must be corrected prior to initiation.

• Cardiogenic shock
• Sick sinus syndrome, second- or third-degree atrioventricular (AV) block, or bradycardia causing syncope without a functioning pacemaker
• Known hypersensitivity to amiodarone or any of its components, including iodine

Important risks and monitoring requirements include:

• Pulmonary toxicity: Can cause serious lung inflammation, including fatal pneumonitis or fibrosis. Baseline and periodic chest X-rays and pulmonary function tests are essential. Monitor for cough and progressive shortness of breath; discontinue therapy if pulmonary toxicity is suspected.
• Hepatic injury: Liver damage can be life-threatening. Monitor liver enzymes before and during treatment. Discontinue or reduce dose if liver enzymes rise above three times normal or double in patients with elevated baseline.
• Worsening arrhythmias: May exacerbate current arrhythmias or provoke new ones including ventricular fibrillation and torsade de pointes, especially with electrolyte disturbances.
• Thyroid abnormalities: Can cause hypo- or hyperthyroidism. Monitor thyroid function regularly, especially in elderly and patients with thyroid history.
• Bradycardia: Symptomatic slow heart rates or sinus arrest may require pacemaker insertion.
• Visual effects: May lead to corneal microdeposits, optic neuropathy, and sometimes serious vision loss. Regular eye exams are recommended.
• Photosensitivity and skin discoloration: Skin may become sensitive to sunlight, with possible blue-gray discoloration on exposed areas.
• Peripheral neuropathy: Chronic use may cause nerve damage which can persist after stopping treatment.
• Use under specialist supervision: Initiate treatment in a monitored setting with cardiac resuscitation capability.

Common side effects include:

• Nausea, vomiting, constipation, abdominal pain
• Photosensitivity (sun sensitivity) and solar dermatitis
• Visual disturbances, corneal microdeposits
• Thyroid disorders (hypothyroidism or hyperthyroidism)
• Cardiac arrhythmias, congestive heart failure, symptomatic bradycardia
• Fatigue, tremor, dizziness, headache, sleep disturbances, lack of coordination
• Elevated liver enzymes
• Pulmonary inflammation or fibrosis
• Flushing, abnormal taste or smell, edema, abnormal salivation

Serious but less common adverse effects reported during postmarketing:

• Severe hepatic injury including hepatitis and cirrhosis
• Severe skin reactions including toxic epidermal necrolysis and Stevens-Johnson syndrome
• Neurologic disorders such as parkinsonism and demyelinating polyneuropathy
• Hematologic abnormalities like aplastic anemia and agranulocytosis
• Respiratory complications including eosinophilic pneumonia and bronchiolitis obliterans organizing pneumonia
• Cardiac hypotension and sinus arrest

Key interactions include:

• Concomitant use with ledipasvir/sofosbuvir or sofosbuvir with simeprevir can cause severe bradycardia, sometimes requiring pacemaker insertion; heart rate should be monitored closely when initiating these antivirals in patients on or recently discontinuing amiodarone.
• Use with drugs that affect electrolyte balance (diuretics, laxatives, corticosteroids, amphotericin B) may increase risk of QT prolongation and arrhythmias.
• Concurrent use with other antiarrhythmics or negative chronotropic agents increases risk of bradycardia.

Pregnancy: Amiodarone may cause fetal harm including cardiac, thyroid, neurological, growth, and developmental problems. Use in pregnancy only if the potential benefit justifies the risk.

Lactation: No specific data provided.